Sequential pembrolizumab may be optimal timing with chemoradiotherapy in head/neck cancer

CHICAGO — A sequential schedule of fixed-dose pembrolizumab with chemoradiotherapy conferred numerically higher PFS rates vs. concurrent timing of the drug among patients with locally advanced head and neck cancer, study results showed.
Researchers initiated the randomized phase 2 study among patients with intermediate- or high-risk, previously untreated disease to identify the preferred fixed-dose pembrolizumab (Keytruda, Merck) regimen for future testing.
“Sequential pembrolizumab may be the preferred regimen to compare in future trials,” David Anthony Clump II, MD, PhD,

CHICAGO — A sequential schedule of fixed-dose pembrolizumab with chemoradiotherapy conferred numerically higher PFS rates vs. concurrent timing of the drug among patients with locally advanced head and neck cancer, study results showed.
Researchers initiated the randomized phase 2 study among patients with intermediate- or high-risk, previously untreated disease to identify the preferred fixed-dose pembrolizumab (Keytruda, Merck) regimen for future testing.
“Sequential pembrolizumab may be the preferred regimen to compare in future trials,” David Anthony Clump II, MD, PhD,